Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RESEARCH TOOLSreports
Holding RXRX?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.41Last Year’s EPS
-0.42Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Aug 13, 2021
|% Change Since: -6.31%
|Next Earnings Date:May 12, 2021
Earnings Call Sentiment|Positive
The earnings call was largely positive, focusing on the strategic combination of Recursion and Exscientia to leverage their complementary strengths. The announcement highlighted the potential for significant growth and milestone achievement through their expanded pipeline and partnership network. However, challenges such as clinical trial bottlenecks and integration complexities were acknowledged.Company Guidance
During the Q2 2024 earnings call for Recursion (RXRX) on August 8, 2024, key guidance metrics were discussed regarding the company's strategic direction and financial outlook. Recursion announced a combination with Exscientia, highlighting a pipeline of nearly 10 clinical readouts expected over the next 18 months, signaling significant progress in the development of next-generation medicines. The combined entities boast approximately $850 million in cash, projecting operational synergies that extend their financial runway into 2027, with annual savings over $100 million. The collaboration is expected to drive approximately $200 million in milestone achievements over the next two years, with potential for over $20 billion in milestones before royalties through existing partnerships. Furthermore, the strategic merger aims to leverage Exscientia's automated synthesis platform and Recursion's extensive biological exploration capabilities, enhancing drug discovery efficiency and reinforcing their positions as leaders in technology-enabled drug development. The transaction details specify that Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock per Exscientia share, with the transaction anticipated to close by early 2025, pending shareholder approvals.Business Combination Announcement
Recursion announced a combination with Exscientia, creating a pipeline of nearly 10 readouts in the next 18 months. The combined companies have roughly $850 million in cash and expect operational synergies to extend their runway into 2027.
Strong Partnership Network
Recursion has partnerships with major companies like Roche, Genentech, and Bayer, while Exscientia partners with Sanofi and Merck KGaA. The combination aims to leverage these partnerships for potential milestones worth over $20 billion.
Innovative Platform Integration
Recursion's focus on biology and Exscientia's precision chemistry platform will combine to create an end-to-end solution for drug discovery, including automated synthesis to improve efficiency and reduce costs.
Potential Milestones
The combined company could achieve approximately $200 million in milestones over the next two years, with the potential for more than $20 billion in milestones before royalties.
Pipeline Expansion
Recursion and Exscientia's combined pipeline includes significant focus on precision oncology and rare diseases, with plans to explore immunology, leveraging strengths from both companies.
---
RXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $6.97 | $6.93 | -0.57% |
| Aug 08, 2024 | $6.37 | $6.64 | +4.24% |
| May 09, 2024 | $8.64 | $8.60 | -0.46% |
| Feb 27, 2024 | $15.52 | $12.94 | -16.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Recursion Pharmaceuticals (RXRX) report earnings?
Recursion Pharmaceuticals (RXRX) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Recursion Pharmaceuticals (RXRX) earnings time?
Recursion Pharmaceuticals (RXRX) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RXRX EPS forecast?
RXRX EPS forecast for the fiscal quarter 2024 (Q4) is -0.41.
---